Background The role of mineralocorticoid receptor antagonists (MRAs) in acute myocardial infarction (MI) remains controversial, with conflicting evidence from landmark trials. We aimed to assess the ...

Mineralocorticoid receptor antagonists (MRAs) reduced the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and reduced ejection fraction (HFrEF) and also in those ...

In a recent meta-analysis published in The Lancet, researchers investigated the effect of steroidal and nonsteroidal mineralocorticoid receptor antagonists (MRAs) on patients with heart failure (HF) ...

The year saw the emergence of a new version of an old drug that proved beneficial in patients who have heart failure with ...

Combination therapy with a nonsteroidal mineralocorticoid receptor antagonist and an SGLT2 inhibitor reduced albuminuria more ...

QUEBEC CITY — The Canadian Cardiovascular Society (CCS) has updated its guidelines on the management of heart failure (HF) with nonreduced ejection fraction (HFnrEF), highlighting the role that SGLT2 ...

Please provide your email address to receive an email when new articles are posted on . GLP-1 benefits persist regardless of background SGLT2 inhibitor use. Optimal strategy for heart failure ...

What if there were a straightforward and relatively inexpensive way to lower the incidence of heart failure (HF), renal disease, stroke, and cognitive impairment? Cardiologist Bertram Pitt, MD, said ...